Hub : Traits :

Medication for cholesterol

23 significantly associated models · 19 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 109605305 110183021 1 1 1.9e-07 3.8e-07 6.1e-01 99 SORT1
2 1 112761639 113496790 2 1 7.2e-10 1.4e-09 5.1e-04 67 RHOC
3 2 27467598 27949052 1 1 1.2e-07 2.2e-07 1.0e+00 100 FNDC4
4 2 48517552 49073574 1 1 2.1e-07 1.1e-06 8.8e-01 100 STON1
5 3 10617048 12293966 1 1 2.1e-07 5.3e-08 5.8e-02 88 ATG7
6 4 103091730 104503936 1 1 2.0e-07 1.5e-06 7.8e-01 100 CISD2
7 6 160071844 161571560 1 1 6.7e-08 8.8e-08 3.9e-02 85 SLC22A3
8 7 26969253 27468350 1 1 5.1e-09 3.7e-08 1.4e-01 93 HOXA10
9 7 129917130 131315092 1 1 2.4e-07 5.2e-08 5.8e-03 74 RP11-138A9.1
10 11 1242690 2640824 1 1 2.7e-08 6.6e-09 2.7e-02 86 TNNT3
11 11 99859184 101559718 2 1 7.1e-08 1.9e-07 6.3e-01 99 TMEM133
12 12 111154626 112582540 1 1 1.5e-07 2.0e-11 1.4e-05 58 SH2B3
13 16 3969463 5441125 2 2 4.8e-09 6.3e-08 3.2e-01 97 MGRN1 NUDT16L1
14 16 89281093 90172696 1 1 2.9e-07 8.0e-06 1.3e-02 69 MC1R
15 19 48918157 49452462 2 1 1.5e-09 4.3e-07 4.9e-01 98 NTN5

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Bipolar Disorder (2018) 1.38 1 0 0.0 0.00 1.0e+00 FNDC4
Bipolar Disorder or Schizophrenia 1.32 3 0 0.0 0.00 1.0e+00 CISD2 NTN5 RHOC
Depressed Affect (Nagel 2018) 1.53 2 0 0.0 0.00 1.0e+00 SH2B3 STON1
Depression (Nagel 2018) 1.60 1 0 0.0 0.00 1.0e+00 STON1
Neuroticism (Nagel 2018) 1.28 2 0 0.0 0.00 1.0e+00 ATG7 CISD2
Schizophrenia (2018) 1.13 2 0 0.0 0.00 1.0e+00 CISD2 RHOC
Schizophrenia vs Biploar Disorder 1.71 1 0 0.0 0.00 1.0e+00 FNDC4
Worry (Nagel 2018) 0.86 1 0 0.0 0.00 1.0e+00 ATG7
Crohns Disease (2017) 3.01 2 2 4.4 0.00 1.0e+00 FNDC4 NTN5
Irritable Bowel Disease (IBD) 2.14 3 1 2.2 0.00 1.0e+00 FNDC4 NTN5 SH2B3
Ulcerative Colitis (UC) 1.41 1 0 0.0 0.00 1.0e+00 CISD2
Reaction Time 1.99 1 1 2.2 0.00 1.0e+00 SH2B3
Breast Cancer 3.36 1 1 2.2 0.00 1.0e+00 TNNT3
Prostate Cancer 1.56 1 0 0.0 0.00 1.0e+00 HOXA10
Bipolar Disorder (2011) 1.82 1 0 0.0 0.00 1.0e+00 FNDC4
Body Mass Index (BMI) (2010) 2.89 1 0 0.0 0.00 1.0e+00 NUDT16L1
Coronary Artery Disease (CAD) 3.25 2 0 0.0 0.00 1.0e+00 SH2B3 SLC22A3
Crohns Disease (2012) 1.22 1 0 0.0 0.00 1.0e+00 FNDC4
Fasting Glucose 6.92 2 1 2.2 0.00 1.0e+00 CISD2 FNDC4
HDL Cholesterol 3.10 2 2 4.4 0.00 1.0e+00 RP11-138A9.1 SORT1
LDL Cholesterol 32.80 4 1 2.2 -0.67 3.3e-01 FNDC4 NTN5 SH2B3 SORT1
Lupus 1.41 2 0 0.0 0.00 1.0e+00 NTN5 SH2B3
Primary Biliary Cirrhosis 3.48 3 1 2.2 0.00 1.0e+00 CISD2 FNDC4 SH2B3
Rheumatoid Arthritis 1.59 1 0 0.0 0.00 1.0e+00 SH2B3
Schizophrenia (2014) 1.34 1 0 0.0 0.00 1.0e+00 CISD2
Triglycerides 25.08 2 1 2.2 0.00 1.0e+00 FNDC4 NTN5
Type 2 Diabetes (T2D) (2012) 2.84 2 0 0.0 0.00 1.0e+00 CISD2 RP11-138A9.1
Blood Eosinophil Count 11.66 2 2 4.4 0.00 1.0e+00 RP11-138A9.1 SH2B3
Blood Platelet Count 5.88 8 6 13.3 -0.67 7.1e-02 FNDC4 MGRN1 NTN5 NUDT16L1 RHOC SH2B3 SLC22A3 STON1
Blood Red Count 2.96 7 3 6.7 -0.11 8.1e-01 FNDC4 MC1R MGRN1 NUDT16L1 RHOC RP11-138A9.1 SH2B3
Blood White Count 8.54 7 4 8.9 -0.71 7.1e-02 FNDC4 MC1R MGRN1 NUDT16L1 RP11-138A9.1 SH2B3 TMEM133
Heel T-Score 1.14 5 2 4.4 0.39 5.2e-01 ATG7 HOXA10 RHOC SORT1 TMEM133
BMI 1.50 6 1 2.2 0.43 3.9e-01 ATG7 CISD2 FNDC4 RP11-138A9.1 SLC22A3 STON1
Height 1.89 13 7 15.6 0.86 1.4e-04 ATG7 FNDC4 HOXA10 MC1R MGRN1 NTN5 NUDT16L1 RHOC SH2B3 SLC22A3 SORT1 TMEM133 TNNT3
Waist Hip Ratio (WHR) 2.79 5 3 6.7 -0.78 1.2e-01 NTN5 RP11-138A9.1 SLC22A3 TMEM133 TNNT3
Systolic Blood Pressure 16.79 13 10 22.2 -0.90 2.6e-05 ATG7 FNDC4 HOXA10 MC1R MGRN1 NTN5 NUDT16L1 RHOC RP11-138A9.1 SH2B3 SLC22A3 TMEM133 TNNT3
Smoking Status 1.06 1 0 0.0 0.00 1.0e+00 SORT1
Allergy or Eczema 1.92 3 0 0.0 0.00 1.0e+00 CISD2 FNDC4 SH2B3
Cardiovascular Disease 16.34 14 10 22.2 -0.94 4.2e-07 ATG7 CISD2 FNDC4 HOXA10 MGRN1 NTN5 NUDT16L1 RHOC RP11-138A9.1 SH2B3 SLC22A3 SORT1 TMEM133 TNNT3
Hypothyroidism (self reported) 8.52 3 1 2.2 0.00 1.0e+00 MC1R NTN5 SH2B3
Type 2 Diabetes (T2D) (2018) 4.18 4 1 2.2 -0.23 7.7e-01 FNDC4 RP11-138A9.1 SH2B3 SLC22A3
Lung FEV1/FVC ratio 1.97 4 2 4.4 0.61 3.9e-01 ATG7 NTN5 SORT1 TMEM133
Lung FVC 1.43 5 0 0.0 -0.24 7.0e-01 CISD2 FNDC4 HOXA10 SH2B3 STON1
Neuroticism 1.22 1 0 0.0 0.00 1.0e+00 ATG7
Chronotype (morning person) 1.66 1 0 0.0 0.00 1.0e+00 NTN5
Hair Pigment 57.83 6 2 4.4 -0.26 6.2e-01 ATG7 FNDC4 MC1R RP11-138A9.1 SH2B3 TMEM133
Tanning 32.81 4 2 4.4 0.28 7.2e-01 FNDC4 MC1R SH2B3 TMEM133
Hand grip strength (left) 2.16 5 0 0.0 0.68 2.0e-01 FNDC4 MGRN1 NUDT16L1 RHOC TNNT3
Number of treatments/medications taken 8.68 9 4 8.9 -0.97 9.8e-06 CISD2 FNDC4 MGRN1 NTN5 NUDT16L1 RHOC SH2B3 SORT1 TMEM133
Average weekly spirits intake 1.81 1 0 0.0 0.00 1.0e+00 NTN5
Sensitivity / hurt feelings 1.05 1 0 0.0 0.00 1.0e+00 CISD2
Relative age of first facial hair 4.36 3 3 6.7 0.00 1.0e+00 ATG7 FNDC4 MC1R
Other serious medical condition/disability diagnosed by doctor 1.62 1 0 0.0 0.00 1.0e+00 SORT1
Systolic blood pressure, automated reading 11.60 10 8 17.8 -0.92 1.6e-04 ATG7 HOXA10 MC1R MGRN1 NTN5 NUDT16L1 RHOC SH2B3 TMEM133 TNNT3
Eye problems/disorders: Diabetes related eye disease 1.74 1 0 0.0 0.00 1.0e+00 MC1R
Angina 6.29 3 2 4.4 0.00 1.0e+00 SLC22A3 SORT1 TMEM133
Medication for hormone replacement therapy 1.97 1 0 0.0 0.00 1.0e+00 STON1
Medication: Metformin 3.45 3 1 2.2 0.00 1.0e+00 CISD2 FNDC4 RP11-138A9.1
Diabetes (father) 2.74 1 0 0.0 0.00 1.0e+00 FNDC4
Diabetes (mother) 2.06 1 0 0.0 0.00 1.0e+00 FNDC4
Impedance of leg (right) 2.46 5 1 2.2 -0.41 4.9e-01 ATG7 FNDC4 MC1R RHOC TMEM133
Leg fat-free mass (left) 3.02 6 1 2.2 0.87 2.4e-02 FNDC4 NUDT16L1 SH2B3 SLC22A3 SORT1 TMEM133
Trunk fat percentage 2.47 6 3 6.7 0.77 7.5e-02 HOXA10 MC1R NUDT16L1 RP11-138A9.1 SLC22A3 STON1
Hand grip strength (right) 1.86 3 0 0.0 0.00 1.0e+00 FNDC4 NUDT16L1 RHOC
Average weekly fortified wine intake 1.57 1 0 0.0 0.00 1.0e+00 MC1R
Fed-up feelings 2.17 2 1 2.2 0.00 1.0e+00 SH2B3 STON1
Frequency of unenthusiasm / disinterest in last 2 weeks 1.19 1 0 0.0 0.00 1.0e+00 SH2B3
Relative age voice broke 1.57 1 0 0.0 0.00 1.0e+00 MC1R
Taking other prescription medications 3.43 2 1 2.2 0.00 1.0e+00 CISD2 SH2B3
Age when periods started (menarche) 1.69 2 0 0.0 0.00 1.0e+00 NTN5 STON1
Heel bone mineral density (BMD) T-score, automated (left) 1.54 2 0 0.0 0.00 1.0e+00 CISD2 TMEM133
High blood pressure 15.16 12 9 20.0 -0.95 1.6e-06 ATG7 CISD2 HOXA10 MC1R MGRN1 NTN5 NUDT16L1 RHOC RP11-138A9.1 SH2B3 TMEM133 TNNT3
Hayfever, allergic rhinitis or eczema 1.66 2 0 0.0 0.00 1.0e+00 FNDC4 SH2B3
Medication: Atenolol 7.63 6 1 2.2 -0.98 8.6e-04 HOXA10 RHOC RP11-138A9.1 SH2B3 TMEM133 TNNT3
Medication: Levothyroxine sodium 7.01 2 1 2.2 0.00 1.0e+00 NTN5 SH2B3
Sitting height 1.94 6 1 2.2 0.75 8.7e-02 ATG7 FNDC4 NTN5 NUDT16L1 SLC22A3 TMEM133
High blood pressure (mother) 5.03 5 0 0.0 -0.99 5.2e-04 HOXA10 RHOC SH2B3 TMEM133 TNNT3
Body mass index (BMI) 1.06 1 0 0.0 0.00 1.0e+00 FNDC4
Impedance of leg (left) 2.61 5 1 2.2 -0.35 5.6e-01 ATG7 FNDC4 MC1R RHOC TMEM133
Leg predicted mass (left) 3.02 6 1 2.2 0.87 2.4e-02 FNDC4 NUDT16L1 SH2B3 SLC22A3 SORT1 TMEM133
Trunk fat mass 2.24 7 0 0.0 0.78 3.7e-02 FNDC4 HOXA10 MC1R NUDT16L1 RP11-138A9.1 SLC22A3 STON1
Waist circumference 1.05 2 0 0.0 0.00 1.0e+00 FNDC4 NUDT16L1
Past tobacco smoking 1.68 1 0 0.0 0.00 1.0e+00 SH2B3
Had menopause 2.68 1 0 0.0 0.00 1.0e+00 MC1R
Forced vital capacity (FVC) 1.79 4 1 2.2 0.99 9.5e-03 CISD2 NUDT16L1 RHOC TMEM133
Heel bone mineral density (BMD) T-score, automated (right) 1.42 2 0 0.0 0.00 1.0e+00 ATG7 TMEM133
Qualifications: None of the above 1.59 1 0 0.0 0.00 1.0e+00 NUDT16L1
Mouth/teeth dental problems 2.00 2 0 0.0 0.00 1.0e+00 CISD2 NTN5
Heart attack 4.94 3 2 4.4 0.00 1.0e+00 SH2B3 SLC22A3 SORT1
Allergy 1.34 1 0 0.0 0.00 1.0e+00 CISD2
Diabetes (self-reported) 3.38 3 1 2.2 0.00 1.0e+00 CISD2 FNDC4 RP11-138A9.1
Medication: Ramipril 7.09 7 1 2.2 -0.97 3.2e-04 CISD2 HOXA10 MGRN1 RHOC SH2B3 SLC22A3 TMEM133
Medication: Simvastatin 12.72 6 3 6.7 -0.89 1.9e-02 FNDC4 NTN5 RP11-138A9.1 SLC22A3 SORT1 TMEM133
Illnesses of siblings 4.50 4 0 0.0 0.98 2.0e-02 CISD2 RHOC SH2B3 TMEM133
Weight 2.40 5 1 2.2 0.71 1.8e-01 FNDC4 NUDT16L1 SH2B3 SLC22A3 STON1
Impedance of arm (right) 3.91 8 2 4.4 -0.09 8.4e-01 ATG7 CISD2 FNDC4 HOXA10 NTN5 RP11-138A9.1 SH2B3 TNNT3
Arm fat percentage (right) 1.57 4 1 2.2 0.68 3.2e-01 HOXA10 RP11-138A9.1 SLC22A3 STON1
Trunk fat-free mass 4.24 9 2 4.4 0.73 2.5e-02 FNDC4 MC1R MGRN1 NTN5 NUDT16L1 SH2B3 SLC22A3 SORT1 TMEM133
Hip circumference 2.51 6 3 6.7 0.98 7.0e-04 FNDC4 NTN5 NUDT16L1 RP11-138A9.1 SH2B3 SLC22A3
Time employed in main current job 1.27 1 0 0.0 0.00 1.0e+00 MC1R
Alcohol intake versus 10 years previously 3.56 2 1 2.2 0.00 1.0e+00 FNDC4 NTN5
Father's age at death 3.33 2 1 2.2 0.00 1.0e+00 SH2B3 SORT1
Frequency of tiredness / lethargy in last 2 weeks 1.77 1 0 0.0 0.00 1.0e+00 SH2B3
Number of live births 1.36 1 0 0.0 0.00 1.0e+00 CISD2
Forced expiratory volume in 1-second (FEV1) 1.79 3 0 0.0 0.00 1.0e+00 NUDT16L1 RHOC TMEM133
Pulse rate 3.19 1 1 2.2 0.00 1.0e+00 FNDC4
Qualifications: A levels/AS levels or equivalent 1.17 1 0 0.0 0.00 1.0e+00 NUDT16L1
Serious illness, injury or assault of a close relative in last 2 years 2.02 1 0 0.0 0.00 1.0e+00 NTN5
Mouth/teeth dental problems: Dentures 2.75 2 1 2.2 0.00 1.0e+00 FNDC4 NTN5
Medication: Ibuprofen (e.g. Nurofen) 1.26 1 0 0.0 0.00 1.0e+00 SLC22A3
Medication: Cholesterol lowering 15.37 5 4 8.9 -0.91 3.4e-02 FNDC4 NTN5 SLC22A3 SORT1 TMEM133
Medication: Lansoprazole 1.60 1 0 0.0 0.00 1.0e+00 SH2B3
Illnesses of mother 4.32 4 0 0.0 1.00 4.5e-03 HOXA10 NTN5 SH2B3 TMEM133
Forced expiratory volume in 1-second (FEV1), Best measure 1.48 3 0 0.0 0.00 1.0e+00 NUDT16L1 RHOC TMEM133
Impedance of arm (left) 4.31 8 2 4.4 0.07 8.6e-01 ATG7 CISD2 FNDC4 HOXA10 MC1R RP11-138A9.1 SH2B3 TNNT3
Arm fat mass (right) 1.61 6 0 0.0 0.77 7.2e-02 FNDC4 HOXA10 NUDT16L1 RP11-138A9.1 SLC22A3 STON1
Trunk predicted mass 4.24 9 2 4.4 0.73 2.5e-02 FNDC4 MC1R MGRN1 NTN5 NUDT16L1 SH2B3 SLC22A3 SORT1 TMEM133
Standing height 2.07 8 7 15.6 0.97 5.0e-05 FNDC4 MGRN1 NTN5 NUDT16L1 RHOC SH2B3 SLC22A3 SORT1
Seen doctor (GP) for nerves, anxiety, tension or depression 1.26 1 0 0.0 0.00 1.0e+00 MC1R
Hair/balding pattern: Pattern 4 1.44 2 0 0.0 0.00 1.0e+00 ATG7 NUDT16L1
Birth weight of first child 3.99 2 1 2.2 0.00 1.0e+00 ATG7 SH2B3
Peak expiratory flow (PEF) 1.80 1 1 2.2 0.00 1.0e+00 NTN5
Qualifications: O levels/GCSEs or equivalent 2.58 1 1 2.2 0.00 1.0e+00 NUDT16L1
Blood clot in the leg (DVT) 1.83 2 0 0.0 0.00 1.0e+00 MC1R SH2B3
Headache pain in last month 2.05 1 0 0.0 0.00 1.0e+00 CISD2
Medication for cholesterol, blood pressure or diabetes 10.01 7 3 6.7 0.96 6.8e-04 CISD2 FNDC4 NTN5 RHOC SH2B3 SORT1 TMEM133
Gout (self-reported) 7.18 2 1 2.2 0.00 1.0e+00 FNDC4 SH2B3
Hypothyroidism/myxoedema (self-reported) 7.13 3 1 2.2 0.00 1.0e+00 MC1R NTN5 SH2B3
Medication: Amlodipine 9.23 6 3 6.7 -0.98 9.2e-04 HOXA10 MC1R MGRN1 RHOC TMEM133 TNNT3
Birth weight 2.94 3 1 2.2 0.00 1.0e+00 HOXA10 NTN5 SH2B3
High blood pressure (siblings) 5.81 6 0 0.0 -0.98 3.8e-04 FNDC4 MGRN1 RHOC SH2B3 TMEM133 TNNT3
Forced vital capacity (FVC), Best measure 1.52 2 0 0.0 0.00 1.0e+00 NUDT16L1 RHOC
Body fat percentage 2.16 5 2 4.4 0.70 1.9e-01 HOXA10 MC1R RP11-138A9.1 SLC22A3 STON1
Leg fat percentage (right) 1.53 3 0 0.0 0.00 1.0e+00 HOXA10 RP11-138A9.1 STON1
Arm fat-free mass (right) 3.90 8 2 4.4 0.76 2.9e-02 CISD2 FNDC4 NTN5 NUDT16L1 SH2B3 SLC22A3 SORT1 TMEM133
Exposure to tobacco smoke outside home 1.53 1 0 0.0 0.00 1.0e+00 SH2B3
Comparative body size at age 10 2.86 4 2 4.4 0.85 1.5e-01 ATG7 FNDC4 MC1R NTN5
Number of children fathered 2.24 1 0 0.0 0.00 1.0e+00 NTN5
Reason for reducing amount of alcohol drunk: Health precaution 1.91 1 0 0.0 0.00 1.0e+00 CISD2
Pulse wave peak to peak time 2.06 1 0 0.0 0.00 1.0e+00 NUDT16L1
Medication for pain relief, constipation, heartburn 2.98 3 0 0.0 0.00 1.0e+00 CISD2 NUDT16L1 SORT1
Neck or shoulder pain in last month 1.58 1 0 0.0 0.00 1.0e+00 MC1R
Medication: Blood pressure 9.75 8 4 8.9 -0.95 3.9e-04 ATG7 CISD2 HOXA10 MGRN1 RHOC SH2B3 TMEM133 TNNT3
Angina (self-reported) 6.52 3 2 4.4 0.00 1.0e+00 SLC22A3 SORT1 TMEM133
Migraine (self-reported) 1.62 1 0 0.0 0.00 1.0e+00 CISD2
Medication: Ibuprofen 1.46 1 0 0.0 0.00 1.0e+00 SLC22A3
Medication: Allopurinol 6.38 2 1 2.2 0.00 1.0e+00 FNDC4 SH2B3
Mean time to correctly identify matches 2.55 1 1 2.2 0.00 1.0e+00 SH2B3
Heart disease (mother) 3.60 1 1 2.2 0.00 1.0e+00 SLC22A3
Whole body fat mass 1.97 7 0 0.0 0.76 4.7e-02 FNDC4 HOXA10 MC1R NUDT16L1 RP11-138A9.1 SLC22A3 STON1
Leg fat mass (right) 1.76 5 0 0.0 0.61 2.8e-01 FNDC4 HOXA10 RP11-138A9.1 SLC22A3 STON1
Arm predicted mass (right) 3.91 7 2 4.4 0.85 1.6e-02 FNDC4 NTN5 NUDT16L1 SH2B3 SLC22A3 SORT1 TMEM133
Pulse rate, automated reading 4.25 4 1 2.2 -0.82 1.8e-01 FNDC4 MGRN1 NUDT16L1 SORT1
Alcohol intake frequency. 6.93 3 2 4.4 0.00 1.0e+00 CISD2 FNDC4 NTN5
Comparative height size at age 10 2.84 7 3 6.7 0.80 3.2e-02 FNDC4 MC1R NTN5 NUDT16L1 SH2B3 SLC22A3 SORT1
Overall health rating 2.45 4 0 0.0 -0.99 1.0e-02 ATG7 CISD2 MGRN1 STON1
Chest pain or discomfort 2.10 1 0 0.0 0.00 1.0e+00 NTN5
Illness, injury, bereavement, stress in last 2 years 1.35 1 0 0.0 0.00 1.0e+00 MC1R
Medication: Aspirin 6.65 3 2 4.4 0.00 1.0e+00 SH2B3 SLC22A3 SORT1
Hypertension (Self-reported) 15.14 14 10 22.2 -0.94 5.6e-07 ATG7 CISD2 HOXA10 MC1R MGRN1 NTN5 NUDT16L1 RHOC RP11-138A9.1 SH2B3 SLC22A3 STON1 TMEM133 TNNT3
Illnesses of father: Heart disease 6.38 4 2 4.4 -0.96 3.9e-02 FNDC4 SH2B3 SLC22A3 SORT1
Illnesses of siblings: Diabetes 1.39 1 0 0.0 0.00 1.0e+00 FNDC4
Smoking status: Previous 1.71 1 0 0.0 0.00 1.0e+00 SH2B3
Forced expiratory volume in 1-second (FEV1), predicted 2.23 3 0 0.0 0.00 1.0e+00 MGRN1 NUDT16L1 RHOC
Whole body fat-free mass 3.83 7 2 4.4 0.86 1.2e-02 FNDC4 NTN5 NUDT16L1 SH2B3 SLC22A3 SORT1 TMEM133
Leg fat-free mass (right) 3.03 6 1 2.2 0.88 2.2e-02 FNDC4 NUDT16L1 SH2B3 SLC22A3 SORT1 TMEM133
Arm fat percentage (left) 1.59 6 1 2.2 0.75 8.4e-02 HOXA10 MC1R NUDT16L1 RP11-138A9.1 SLC22A3 STON1
Average weekly red wine intake 1.43 1 0 0.0 0.00 1.0e+00 SLC22A3
Mood swings 1.34 1 0 0.0 0.00 1.0e+00 SH2B3
Loneliness, isolation 2.02 1 0 0.0 0.00 1.0e+00 SH2B3
Long-standing illness, disability or infirmity 1.78 1 0 0.0 0.00 1.0e+00 SH2B3
Diabetes diagnosed by doctor 4.49 5 1 2.2 -0.29 6.3e-01 CISD2 FNDC4 RP11-138A9.1 SH2B3 SLC22A3
Qualifications: nursing, teaching 2.01 2 0 0.0 0.00 1.0e+00 NUDT16L1 SH2B3
Mouth/teeth dental problems: Mouth ulcers 1.47 1 0 0.0 0.00 1.0e+00 SH2B3
Medication: Laxatives (e.g. Dulcolax, Senokot) 1.52 1 0 0.0 0.00 1.0e+00 FNDC4
Back pain experienced in last month 1.12 1 0 0.0 0.00 1.0e+00 SH2B3
Mineral and other dietary supplements 1.61 1 0 0.0 0.00 1.0e+00 SLC22A3
Osteoporosis (self-reported) 1.58 1 0 0.0 0.00 1.0e+00 FNDC4
Osteoarthritis (self-reported) 1.73 1 0 0.0 0.00 1.0e+00 NUDT16L1
Medication: Aspirin 6.44 4 2 4.4 -0.98 1.7e-02 CISD2 SH2B3 SLC22A3 SORT1
Medication: Gliclazide 2.86 2 0 0.0 0.00 1.0e+00 CISD2 FNDC4
Illnesses of father: None of the above (group 1) 3.48 2 0 0.0 0.00 1.0e+00 SH2B3 SLC22A3
Forced expiratory volume in 1-second (FEV1), predicted percentage 1.13 1 0 0.0 0.00 1.0e+00 TMEM133
Whole body water mass 3.88 8 2 4.4 0.86 5.6e-03 FNDC4 MGRN1 NTN5 NUDT16L1 SH2B3 SLC22A3 SORT1 TMEM133
Leg predicted mass (right) 3.01 6 1 2.2 0.88 2.2e-02 FNDC4 NUDT16L1 SH2B3 SLC22A3 SORT1 TMEM133
Arm fat mass (left) 1.69 6 0 0.0 0.75 8.3e-02 FNDC4 HOXA10 NUDT16L1 RP11-138A9.1 SLC22A3 STON1
Number of self-reported non-cancer illnesses 7.85 7 3 6.7 -0.98 1.6e-04 CISD2 FNDC4 MGRN1 NTN5 NUDT16L1 SH2B3 TMEM133
Mother's age at death 1.88 1 0 0.0 0.00 1.0e+00 SH2B3
Medication: Blood pressure 18.71 14 9 20.0 -0.98 5.2e-10 ATG7 CISD2 HOXA10 MC1R MGRN1 NTN5 NUDT16L1 RHOC RP11-138A9.1 SH2B3 SLC22A3 STON1 TMEM133 TNNT3
Supplements: Fish oil (including cod liver oil) 1.98 1 0 0.0 0.00 1.0e+00 SLC22A3
High cholesterol (Self-reported) 23.51 5 5 11.1 -0.92 2.9e-02 FNDC4 NTN5 SLC22A3 SORT1 TMEM133
Medication: Bendroflumethiazide 11.02 9 5 11.1 -0.99 3.0e-07 ATG7 CISD2 HOXA10 MGRN1 NTN5 RHOC SH2B3 TMEM133 TNNT3
Medication: Lisinopril 5.18 4 0 0.0 -0.99 1.2e-02 NTN5 RHOC SH2B3 TMEM133
Medication: Atorvastatin 12.82 4 2 4.4 -0.98 2.3e-02 FNDC4 NTN5 SLC22A3 SORT1
Illnesses of father: High blood pressure 3.59 2 0 0.0 0.00 1.0e+00 SH2B3 TMEM133
Ever smoked 1.41 1 0 0.0 0.00 1.0e+00 SH2B3
Basal metabolic rate 3.49 7 2 4.4 0.87 1.0e-02 FNDC4 NTN5 NUDT16L1 SH2B3 SLC22A3 SORT1 TMEM133
Leg fat percentage (left) 1.49 4 0 0.0 0.48 5.2e-01 HOXA10 MC1R RP11-138A9.1 STON1
Arm fat-free mass (left) 3.87 7 2 4.4 0.78 4.0e-02 CISD2 FNDC4 NTN5 NUDT16L1 SH2B3 SLC22A3 SORT1
Diastolic blood pressure, automated reading 10.72 10 3 6.7 -0.86 1.4e-03 CISD2 HOXA10 MGRN1 NTN5 NUDT16L1 RHOC RP11-138A9.1 SH2B3 TMEM133 TNNT3
Myopia 1.37 1 0 0.0 0.00 1.0e+00 RHOC
Vascular/heart problems diagnosed by doctor 15.17 14 10 22.2 0.94 6.0e-07 ATG7 CISD2 HOXA10 MC1R MGRN1 NTN5 NUDT16L1 RHOC RP11-138A9.1 SH2B3 SLC22A3 STON1 TMEM133 TNNT3
Cholesterol lowering medication 15.33 8 4 8.9 -0.91 1.7e-03 FNDC4 MGRN1 NTN5 NUDT16L1 RP11-138A9.1 SLC22A3 SORT1 STON1
Pain experienced in last month 1.52 1 0 0.0 0.00 1.0e+00 SH2B3
Basal cell carcinoma (self-reported) 1.53 1 0 0.0 0.00 1.0e+00 MC1R
Heart attack/myocardial infarction (self-reported) 4.93 3 2 4.4 0.00 1.0e+00 SH2B3 SLC22A3 SORT1
Deep venous thrombosis (DVT) (self-reported) 1.62 2 0 0.0 0.00 1.0e+00 MC1R SH2B3
Heart disease (siblings) 3.38 2 0 0.0 0.00 1.0e+00 SLC22A3 SORT1
Alcohol drinker status: Previous 2.33 1 0 0.0 0.00 1.0e+00 RP11-138A9.1
Impedance of whole body 3.71 7 3 6.7 0.01 9.8e-01 ATG7 CISD2 FNDC4 MC1R RHOC TMEM133 TNNT3
Leg fat mass (left) 1.76 5 0 0.0 0.60 2.8e-01 FNDC4 HOXA10 RP11-138A9.1 SLC22A3 STON1
Arm predicted mass (left) 3.92 8 2 4.4 0.76 3.0e-02 CISD2 FNDC4 NTN5 NUDT16L1 SH2B3 SLC22A3 SORT1 TMEM133

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 0 0.000 1.5
GTEx Adipose Visceral Omentum 1 0.049 1.6
GTEx Adrenal Gland 0 0.000 1.5
GTEx Artery Aorta 0 0.000 1.6
GTEx Artery Coronary 0 0.000 1.5
GTEx Artery Tibial 2 0.053 1.5
GTEx Brain Caudate basal ganglia 0 0.000 1.4
GTEx Brain Cerebellar Hemisphere 0 0.000 1.5
GTEx Brain Cerebellum 0 0.000 1.5
GTEx Brain Cortex 0 0.000 1.5
GTEx Brain Frontal Cortex BA9 0 0.000 1.6
GTEx Brain Hippocampus 0 0.000 1.4
GTEx Brain Hypothalamus 0 0.000 1.5
GTEx Brain Nucleus accumbens basal ganglia 0 0.000 1.6
GTEx Brain Putamen basal ganglia 0 0.000 1.4
GTEx Breast Mammary Tissue 0 0.000 1.6
GTEx Breast Mammary Tissue (Male) 0 0.000 1.6
GTEx Breast Mammary Tissue (Female) 0 0.000 1.6
GTEx Cells EBV-transformed lymphocytes 0 0.000 1.6
GTEx Cells Transformed fibroblasts 0 0.000 1.6
GTEx Colon Sigmoid 0 0.000 1.6
GTEx Colon Transverse 0 0.000 1.5
GTEx Esophagus Gastroesophageal Junction 0 0.000 1.5
GTEx Esophagus Mucosa 0 0.000 1.5
GTEx Esophagus Muscularis 1 0.031 1.5
GTEx Heart Atrial Appendage 0 0.000 1.6
GTEx Heart Left Ventricle 1 0.065 1.5
GTEx Liver 0 0.000 1.5
GTEx Lung 0 0.000 1.6
GTEx Muscle Skeletal 2 0.069 1.5
GTEx Nerve Tibial 0 0.000 1.5
GTEx Ovary 0 0.000 1.6
GTEx Pancreas 0 0.000 1.6
GTEx Pituitary 0 0.000 1.5
GTEx Prostate 0 0.000 1.6
GTEx Skin Not Sun Exposed Suprapubic 1 0.041 1.6
GTEx Skin Sun Exposed Lower leg 0 0.000 1.5
GTEx Small Intestine Terminal Ileum 0 0.000 1.7
GTEx Spleen 0 0.000 1.6
GTEx Stomach 0 0.000 1.6
GTEx Testis 0 0.000 1.5
GTEx Thyroid 0 0.000 1.6
GTEx Uterus 0 0.000 1.6
GTEx Vagina 0 0.000 1.5
GTEx Whole Blood 1 0.050 1.6
METSIM Adipose 2 0.043 1.5
NTR Blood 0 0.000 1.5
ROSMAP Brain Pre-frontal Cortex 0 0.000 1.6
YFS Blood 2 0.043 1.4
CommonMind Brain Pre-frontal Cortex 2 0.037 1.5
The Cancer Genome Atlas Bladder Urothelial Carcinoma 0 0.000 1.4
The Cancer Genome Atlas Breast Invasive Carcinoma 1 0.023 1.5
The Cancer Genome Atlas Cervical Squamous Cell Carcinoma 0 0.000 1.5
The Cancer Genome Atlas Colon Adenocarcinoma 0 0.000 1.6
The Cancer Genome Atlas Esophageal Carcinoma 0 0.000 1.5
The Cancer Genome Atlas Glioblastoma Multiforme 0 0.000 1.5
The Cancer Genome Atlas Head and Neck Squamous Cell Carcinoma 0 0.000 1.6
The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma 0 0.000 1.5
The Cancer Genome Atlas Kidney Renal Papillary Cell Carcinoma 2 0.098 1.6
The Cancer Genome Atlas Brain Lower Grade Glioma 0 0.000 1.5
The Cancer Genome Atlas Liver Hepatocellular Carcinoma 1 0.090 1.5
The Cancer Genome Atlas Lung Adenocarcinoma 0 0.000 1.5
The Cancer Genome Atlas Lung Squamous Cell Carcinoma 0 0.000 1.5
The Cancer Genome Atlas Ovarian Serous Cystadenocarcinoma 1 0.063 1.6
The Cancer Genome Atlas Pancreatic Adenocarcinoma 0 0.000 1.5
The Cancer Genome Atlas Pheochromocytoma and Paraganglioma 0 0.000 1.5
The Cancer Genome Atlas Prostate Adenocarcinoma 0 0.000 1.4
The Cancer Genome Atlas Rectum Adenocarcinoma 0 0.000 1.6
The Cancer Genome Atlas Soft Tissue Sarcoma 0 0.000 1.5
The Cancer Genome Atlas Skin Cutaneous Melanoma 0 0.000 1.5
The Cancer Genome Atlas Stomach Adenocarcinoma 0 0.000 1.5
The Cancer Genome Atlas Testicular Germ Cell Tumors 0 0.000 1.4
The Cancer Genome Atlas Thyroid Carcinoma 3 0.058 1.5
The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma 0 0.000 1.4